Table SI. Primer and probe sequences for qMSP.

Gene	Sequences before bisulfite conversion (5'-3')	Sequences after bisulfite conversion (5'-3')
NID2	F: CGGTTTCCAGTCCTGCGGAGCAG	F: CGGTTTTTAGTTTTGCGGAGTAG
NID2	P: FAM-TACCGCCTCCGTGGCCGCG-MGB	P: FAM-TATCGTTTTCGTGGTCGCG-MGB
NID2	R: CTTGCCCATTGCTGCGGCCGTCG	R: CTTACCCATTACTACGACCGTCG
CDO1	F: GTCCCAGCGTCGCGAACCACAGC	F: GTTTTAGCGTCGCGAATTATAGC
CDO1	P: VIC-AGAGGCGTTAGGCCGG-MGB	P: VIC-AGAGGCGTTAGGTCGG-MGB
CDO1	R: TCTCCCCCACTTTAACGGCG	R: TCTCCCCCACTTTAACGACG
ACTB	F: CCCCCTGGCGGCCTAAGGACTC	F: TTTTTTGGCGGTTTAAGGATTC
ACTB	P: CY5-CGCCGGAAGTGGCCAGG-MGB	P: CY5-CGTCGGAAGTGGTTAGG-MGB
ACTB	R: CGCGCTGTGAGCCGAGGTCG	R: CGCGCTATAAACCGAAATCG

F, forward; R, reverse; P, probe; NID2, nidogen-2; CDO1, cysteine dioxygenase 1; ACTB, β-actin.

Table SII. Characteristics of participants after propensity score matching.

Characteristics	NC (n=57)	OC (n=57)	P-value
Age, years [median (range)]	62 (50.50-69.50)	60 (54.00-68.00)	0.912
ECOG PS score			0.751
0-2	52 (91.2)	51 (89.5)	
3-4	5 (8.8)	6 (10.5)	
Hypertension	15 (26.3)	20 (35.1)	0.310
Type 2 diabetes mellitus	13 (22.8)	13 (22.8)	1.000

After 1:1 nearest neighbor matching without replacement, 57 patients in the OC group were successfully matched to 57 participants in the NC group. Post-matching analysis revealed no significant differences in baseline characteristics between the two groups (all P>0.05), indicating that the potential confounding effects of hypertension and performance status were effectively balanced. Values are expressed as n (%) unless otherwise specified. ECOG PS, Eastern Cooperative Oncology Group performance status; NC, normal control; OC, ovarian cancer.

Table SIII. Diagnostic values of serum makers for patients with International Federation of Gynecology and Obstetrics stage I-II ovarian cancer.

Marker	Sn, %	Sp, %	Youden index	AUC	P-value	95% CI
NID2	38.5	96.0	0.345	0.560	0.491	0.337-0.783
CDO1	84.6	89.3	0.739	0.916	<0.001	0.846-0.987
CA125	76.9	97.3	0.742	0.893	<0.001	0.766-1.000

CA125, carbohydrate antigen 125; NID2, nidogen-2; CDO1, cysteine dioxygenase 1; Sn, sensitivity; Sp, specificity; AUC, area under the curve.

Table SVI. Diagnostic values of serum makers for patients with International Federation of Gynecology and Obstetrics stage III-IV ovarian cancer.

Marker	Sn, %	Sp, %	Youden index	AUC	P-value	95% CI
NID2	78.0	96.0	0.740	0.810	<0.001	0.720-0.900
CDO1	91.5	69.3	0.608	0.870	<0.001	0.811-0.929
CA125	76.3	93.3	0.696	0.878	<0.001	0.815-0.942

CA125, carbohydrate antigen 125; NID2, nidogen-2; CDO1, cysteine dioxygenase 1; Sn, sensitivity; Sp, specificity; AUC, area under the curve.